Prospects for severe asthma treatment

被引：21

作者：

Calzetta, Luigino ^{[1
]}

Matera, Maria Gabriella ^{[2
]}

Coppola, Angelo ^{[3
]}

Rogliani, Paola ^{[3
,4
]}

机构：

[1] Univ Parma, Dept Med & Surg, Resp Dis & Lung Funct Unit, Parma, Italy

[2] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy

[3] Univ Hosp Tor Vergata, Div Resp Med, Rome, Italy

[4] Univ Roma Tor Vergata, Dept Expt Med, Unit Resp Med, Rome, Italy

来源：

CURRENT OPINION IN PHARMACOLOGY | 2021年 / 56卷

关键词：

Biologics; Biomarkers; Inflammation; Monoclonal antibodies; Severe asthma; SEVERE ALLERGIC-ASTHMA; DOUBLE-BLIND; EOSINOPHILIC ASTHMA; INHALED CORTICOSTEROIDS; MONOCLONAL-ANTIBODY; MEPOLIZUMAB; EFFICACY; BENRALIZUMAB; INFLAMMATION; OMALIZUMAB;

D O I：

10.1016/j.coph.2020.10.021

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Biological drugs are approved to treat patients with severe uncontrolled asthma and are directed against mediators of type 2 immunity. These agents are effective in reducing the risk of exacerbation, maintaining asthma symptom control and reducing the need of systemic corticosteroids. Although biological drugs have revolutionized the management of the disease, to date there are no head-to-head studies across the current available molecules and there remains the need of specific biomarkers for the diagnosis, prognosis and response to treatment. Moreover, there is still an urgent need to identify further molecular targets to offer effective treatments for those patients who are not responsive to the currently available biological drugs, by moving upstream in the inflammatory cascade to inhibit multiple inflammatory pathways and/or identify effective nontype 2 immunity mechanisms.

引用

页码：52 / 60

页数：9

共 72 条

[1] "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis [J].

Alhossan, Abdulaziz ;

Lee, Christopher S. ;

MacDonald, Karen ;

Abraham, Ivo .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2017, 5 (05) :1362-+

[2] Biological treatments for severe asthma [J].

Assaf, Sara M. ;

Hanania, Nicola A. .

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 19 (04) :379-386

[3] Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial [J].

Bachert, Claus ;

Mannent, Leda ;

Naclerio, Robert M. ;

Mullol, Joaquim ;

Ferguson, Berrylin J. ;

Gevaert, Philippe ;

Hellings, Peter ;

Jiao, Lixia ;

Wang, Lin ;

Evans, Robert R. ;

Pirozzi, Gianluca ;

Graham, Neil M. ;

Swanson, Brian ;

Hamilton, Jennifer D. ;

Radin, Allen ;

Gandhi, Namita A. ;

Stahl, Neil ;

Yancopoulos, George D. ;

Sutherland, E. Rand .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (05) :469-479

[4] Biologicals for severe asthma: what we can learn from real-life experiences? [J].

Bagnasco, Diego ;

Caminati, Marco ;

Passalacqua, Giovanni .

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 20 (01) :64-70

[5] One year of mepolizumab. Efficacy and safety in real-life in Italy [J].

Bagnasco, Diego ;

Caminati, Marco ;

Menzella, Francesco ;

Milanese, Manlio ;

Rolla, Giovanni ;

Lombardi, Carlo ;

Bucca, Caterina ;

Heffler, Enrico ;

Paoletti, Giovanni ;

Testino, Elisa ;

Manfredi, Andrea ;

Caruso, Cristiano ;

Guida, Giuseppe ;

Senna, Gianenrico ;

Bonavia, Marco ;

Riccio, Anna Maria ;

Canonica, Giorgio Walter ;

Passalacqua, Giovanni .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2019, 58

[6] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].

Bel, Elisabeth H. ;

Wenzel, Sally E. ;

Thompson, Philip J. ;

Prazma, Charlene M. ;

Keene, Oliver N. ;

Yancey, Steven W. ;

Ortega, Hector G. ;

Pavord, Ian D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197

[7] Biomarkers in asthmatic patients: Has their time come to direct treatment? [J].

Berry, Alalia ;

Busse, William W. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (05) :1317-1324

[8] Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels A Randomized Phase 3 Study [J].

Bjermer, Leif ;

Lemiere, Catherine ;

Maspero, Jorge ;

Weiss, Sivan ;

Zangrilli, James ;

Germinaro, Matthew .

CHEST, 2016, 150 (04) :789-798

[9] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].

Blauvelt, Andrew ;

de Bruin-Weller, Marjolein ;

Gooderham, Melinda ;

Cather, Jennifer C. ;

Weisman, Jamie ;

Pariser, David ;

Simpson, Eric L. ;

Papp, Kim A. ;

Hong, H. Chih-Ho ;

Rubel, Diana ;

Foley, Peter ;

Prens, Errol ;

Griffiths, Christopher E. M. ;

Etoh, Takafumi ;

Pinto, Pedro Herranz ;

Pujol, Ramon M. ;

Szepietowski, Jacek C. ;

Ettler, Karel ;

Kemeny, Lajos ;

Zhu, Xiaoping ;

Akinlade, Bolanle ;

Hultsch, Thomas ;

Mastey, Vera ;

Gadkari, Abhijit ;

Eckert, Laurent ;

Amin, Nikhil ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Stahl, Neil ;

Yancopoulos, George D. ;

Shumel, Brad .

LANCET, 2017, 389 (10086) :2287-2303

[10] Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J].

Bleecker, Eugene R. ;

FitzGerald, J. Mark ;

Chanez, Pascal ;

Papi, Alberto ;

Weinstein, Steven F. ;

Barker, Peter ;

Sproule, Stephanie ;

Gilmartin, Geoffrey ;

Aurivillius, Magnus ;

Werkstrom, Viktoria ;

Goldman, Mitchell .

LANCET, 2016, 388 (10056) :2115-2127

← 1 2 3 4 5 6 7 8 →